Clinical Trial Update: A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing NXT007 to Emicizumab prophylaxis in people with Hemophilia A; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Hemlibra (emicizumab)
• NXT007

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hemophilia A | Phase 3 | Status: RECRUITING